HubsBaker Botts Advises Novartis on Sale of Sandoz Generic Assets to Aurobindo Pharma
Release
Baker Botts L.L.P. is representing Novartis on the U.S. antitrust clearance of its sale of its Sandoz division’s U.S. dermatology business and generic U.S. oral solids portfolio to Aurobindo Pharma U.S.A., Inc.. The parties announced the transaction on September 5, 2018. The Novartis internal antitrust team on the transaction includes Susan Jones (Head Antitrust Legal, Novartis AG) and Ryan Foley (Sr. Corporate Counsel, Antitrust Americas).
The Baker Botts team is led by partners Steve Weissman and Michael Perry, who are supported by associates Matt Adler and Tim Singer. All are in the firm’s antitrust practice group in Washington, DC.
The Baker Botts team is led by partners Steve Weissman and Michael Perry, who are supported by associates Matt Adler and Tim Singer. All are in the firm’s antitrust practice group in Washington, DC.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm whose lawyers practice throughout a network of offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy, technology and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.
